Notice of Investigation on Over-the-Counter Lidocaine Patches
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The U.S. International Trade Commission initiated an investigation into the importation and sale of certain over-the-counter lidocaine patches. This action is in response to a complaint of patent infringement by J.A.R. Laboratories concerning U.S. Patent No. 12,109,181. Companies involved in selling these products into the U.S. market should prepare for possible exclusion orders and cease and desist directives.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Initiation of investigation into over-the-counter lidocaine patch imports
- Potential for exclusion and cease and desist orders
- Alleged patent infringement on U.S. Patent 12,109,181
Obligations
What this law requires
Named respondents must submit written responses to the complaint and notice of investigation within 20 days after the date of service by the Commission, addressing each allegation in the complaint and notice
Companies importing, selling for importation, or selling within the United States over-the-counter topical lidocaine patches must cease such activities if found to infringe claims 1 and 5 of U.S. Patent No. 12,109,181
Failure to file a timely response to the complaint and notice of investigation within 20 days may result in waiver of the right to appear and contest allegations, and authorization for default findings against the respondent
Extensions of time for submitting responses to the complaint and notice of investigation will only be granted upon demonstrating good cause
Respondents must comply with section 210.13 of the Commission's Rules of Practice and Procedure (19 CFR 210.13) when submitting responses to the complaint and notice of investigation